Processa announces sites selected for phase 2b clinical trial to treat patients with ulcerated necrobiosis lipoidica

Hanover, march 17, 2021 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) ("processa" or the "company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient's survival and/or quality of life, today announces that it has selected 5 u.s. clinical sites to enroll patients with ulcerative necrobiosis lipoidica for the company's phase 2b trial “a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of pcs499 in treating ulcerations in patients who have necrobiosis lipoidica.” two to three additional clinical sites will be selected in the future including sites outside the u.s.
PCSA Ratings Summary
PCSA Quant Ranking